Trial
NCT00608881
Coenzyme Q10 in Huntington's Disease (HD)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); University of Rochester
Condition
Huntington's Disease
Intervention
coenzyme Q10
Why stopped
Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-30